Blood test may predict chemo success in colorectal cancer
NCT ID NCT01596790
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether a new blood test called EPISPOT can predict how well chemotherapy works in people with metastatic colorectal cancer. Researchers measured circulating tumor cells in 168 patients before and during treatment. The goal was to see if early changes in these cells could help doctors personalize therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this blood test could help doctors choose the best first-line treatment for metastatic colorectal cancer patients.
- What could go wrong
- This is an observational study, not a treatment trial. The test may not prove reliable enough to change clinical practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Medical Oncology, CHU St Eloi
Montpellier, 34090, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can delivering cancer drug directly to the liver shrink tumors?
- Blood biomarkers could replace invasive biopsies for colorectal cancer monitoring
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Can a Two-Drug combo outsmart resistant colorectal cancer?
- Can a pill boost the immune system to fight Hard-to-Treat cancers?
- Can a Triple-Drug rechallenge tame colorectal cancer?